首页 > 最新文献

Current opinion in rheumatology最新文献

英文 中文
Axial spondyloarthritis guidelines - aiming for maximum impact. 轴性脊柱关节炎指南--旨在产生最大影响。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-04-26 DOI: 10.1097/BOR.0000000000001020
Mathieu Choufani, Jonathan Kay, Joerg Ermann
PURPOSE OF REVIEWThis review discusses international clinical practice guidelines (CPGs) for axial spondyloarthritis (axSpA) focusing on methodology, guideline quality, and implementation.RECENT FINDINGSThe Assessment of SpondyloArthritis International Society/European Alliance of Associations for Rheumatology (ASAS/EULAR) and Pan-American League of Associations for Rheumatology (PANLAR) recently published axSpA CPGs and updates of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) and Asia-Pacific League of Associations for Rheumatology (APLAR) CPGs are expected. GRADE has emerged as the dominant framework for CPG development and has been used by three of the four international axSpA guidelines. Notable differences exist among these guidelines in the way that the recommendations are presented. Two of the four acknowledge the need for implementation strategies, but little detail about this is provided. The few studies that have evaluated the implementation of axSpA CPGs have identified poor adherence to recommendations on physical therapy/exercise and disease activity monitoring. Implementation science has identified many barriers and facilitators affecting guideline uptake, including those related to healthcare professionals and to the guidelines themselves. Creation of a tailored implementation plan simultaneously with the CPG is recommended.SUMMARYWhile methodological rigor in the creation of evidence-based recommendations is the focus of CPG development, recommendations must be presented in a user-friendly format that makes them easy to apply. 'Living guidelines' could facilitate keeping content up to date. Implementation is critical for the success of a CPG and should be emphasized in future axSpA guideline updates. Further research is needed to better understand the factors impacting the successful implementation of axSpA CPGs.
综述目的本综述讨论了针对轴性脊柱关节炎(axSpA)的国际临床实践指南(CPG),重点关注方法、指南质量和实施情况。最新发现国际脊柱关节炎评估协会/欧洲风湿病学协会联盟 (ASAS/EULAR) 和泛美风湿病学协会联盟 (PANLAR) 最近发布了 axSpA CPG,美国风湿病学会/美国脊柱炎协会/软骨关节炎研究与治疗网络 (ACR/SAA/SPARTAN) 和亚太风湿病学协会联盟 (APLAR) CPG 的更新也在预料之中。GRADE 已成为制定 CPG 的主要框架,四份国际 axSpA 指南中的三份都采用了 GRADE。这些指南在提出建议的方式上存在显著差异。四份指南中有两份承认有必要制定实施策略,但提供的细节很少。为数不多的对 axSpA CPGs 实施情况进行评估的研究发现,对物理治疗/运动和疾病活动监测建议的坚持度较低。实施科学发现了许多影响指南采纳的障碍和促进因素,包括与医护人员和指南本身相关的障碍和促进因素。总结虽然循证建议的制定方法严谨是制定 CPG 的重点,但建议必须以用户友好的形式呈现,使其易于应用。活指南 "可以促进内容的不断更新。实施是 CPG 取得成功的关键,应在未来的 axSpA 指南更新中加以强调。需要进一步开展研究,以更好地了解影响 axSpA CPGs 成功实施的因素。
{"title":"Axial spondyloarthritis guidelines - aiming for maximum impact.","authors":"Mathieu Choufani, Jonathan Kay, Joerg Ermann","doi":"10.1097/BOR.0000000000001020","DOIUrl":"https://doi.org/10.1097/BOR.0000000000001020","url":null,"abstract":"PURPOSE OF REVIEW\u0000This review discusses international clinical practice guidelines (CPGs) for axial spondyloarthritis (axSpA) focusing on methodology, guideline quality, and implementation.\u0000\u0000\u0000RECENT FINDINGS\u0000The Assessment of SpondyloArthritis International Society/European Alliance of Associations for Rheumatology (ASAS/EULAR) and Pan-American League of Associations for Rheumatology (PANLAR) recently published axSpA CPGs and updates of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) and Asia-Pacific League of Associations for Rheumatology (APLAR) CPGs are expected. GRADE has emerged as the dominant framework for CPG development and has been used by three of the four international axSpA guidelines. Notable differences exist among these guidelines in the way that the recommendations are presented. Two of the four acknowledge the need for implementation strategies, but little detail about this is provided. The few studies that have evaluated the implementation of axSpA CPGs have identified poor adherence to recommendations on physical therapy/exercise and disease activity monitoring. Implementation science has identified many barriers and facilitators affecting guideline uptake, including those related to healthcare professionals and to the guidelines themselves. Creation of a tailored implementation plan simultaneously with the CPG is recommended.\u0000\u0000\u0000SUMMARY\u0000While methodological rigor in the creation of evidence-based recommendations is the focus of CPG development, recommendations must be presented in a user-friendly format that makes them easy to apply. 'Living guidelines' could facilitate keeping content up to date. Implementation is critical for the success of a CPG and should be emphasized in future axSpA guideline updates. Further research is needed to better understand the factors impacting the successful implementation of axSpA CPGs.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140652584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
50 years of spondyloarthritis: a look back and a look ahead. 脊柱关节炎 50 年:回顾与展望。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-04-25 DOI: 10.1097/BOR.0000000000001019
Philip S Helliwell
PURPOSE OF REVIEWIt is now 50 years since the concept of spondyloarthritis was introduced by Moll, Wright and co-authors from Leeds, UK. This review will review the original concept and mark significant milestones over the last 50 years while looking ahead to developments in the future.RECENT FINDINGSWhile the diseases included under this rubric in the original description may have changed the core conditions remain and are still characterized by axial inflammation as a common feature. Imaging, animal models, genetics and immunology have contributed to our knowledge of the pathogenesis and classification of these diseases and have led to the development of more effective treatments.SUMMARYFuture developments, facilitated by large research consortia, will help build on our current knowledge and will help clarify disease heterogeneity and provide insights into new therapeutic pathways.
综述目的自英国利兹的莫尔、赖特和合著者提出脊柱关节炎的概念以来,至今已有 50 年。本综述将对最初的概念进行回顾,并对过去 50 年中的重要里程碑进行标记,同时展望未来的发展。最新发现虽然最初描述中包含的疾病可能已经发生了变化,但核心病症仍然存在,并且仍然以轴向炎症为共同特征。影像学、动物模型、遗传学和免疫学为我们了解这些疾病的发病机制和分类做出了贡献,并促进了更有效治疗方法的开发。总结在大型研究联盟的推动下,未来的发展将有助于巩固我们现有的知识,并有助于阐明疾病的异质性,为新的治疗途径提供见解。
{"title":"50 years of spondyloarthritis: a look back and a look ahead.","authors":"Philip S Helliwell","doi":"10.1097/BOR.0000000000001019","DOIUrl":"https://doi.org/10.1097/BOR.0000000000001019","url":null,"abstract":"PURPOSE OF REVIEW\u0000It is now 50 years since the concept of spondyloarthritis was introduced by Moll, Wright and co-authors from Leeds, UK. This review will review the original concept and mark significant milestones over the last 50 years while looking ahead to developments in the future.\u0000\u0000\u0000RECENT FINDINGS\u0000While the diseases included under this rubric in the original description may have changed the core conditions remain and are still characterized by axial inflammation as a common feature. Imaging, animal models, genetics and immunology have contributed to our knowledge of the pathogenesis and classification of these diseases and have led to the development of more effective treatments.\u0000\u0000\u0000SUMMARY\u0000Future developments, facilitated by large research consortia, will help build on our current knowledge and will help clarify disease heterogeneity and provide insights into new therapeutic pathways.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140657285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An update on topical therapies for psoriasis. 银屑病外用疗法的最新进展。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-04-24 DOI: 10.1097/BOR.0000000000001018
Emily K Pender, Brian Kirby
PURPOSE OF REVIEWTopical therapies are a mainstay of treatment for mild psoriasis and may be a useful adjunct in treatment of moderate-to-severe psoriasis. This review summarizes recent advances in topical therapies for psoriasis and currently available treatments.RECENT FINDINGSTopical aryl hydrocarbon receptor modulators (tapinarof) and topical phosphodiesterase-4 inhibitors (roflumilast) have been proven effective in randomized controlled trials for psoriasis. Although topical JAK inhibitors have also been studied, none are currently licensed for treatment of psoriasis. Topical corticosteroids and vitamin D analogues remain the most commonly used and widely available topical treatments for psoriasis. Cost may limit use of novel topical agents.SUMMARYAlthough the novel topical agents tapinarof and roflumilast are licensed for treatment of psoriasis by the FDA in the United States, they have not yet been licensed in Europe, and it remains to be seen whether they will be limited by cost.
综述目的局部疗法是治疗轻度银屑病的主要方法,也可能是治疗中重度银屑病的有效辅助疗法。本综述总结了银屑病局部疗法的最新进展以及目前可用的治疗方法。最新发现局部芳基烃受体调节剂(tapinarof)和局部磷酸二酯酶-4抑制剂(roflumilast)已在银屑病随机对照试验中被证实有效。虽然也对外用 JAK 抑制剂进行了研究,但目前还没有任何一种抑制剂被许可用于治疗银屑病。外用皮质类固醇激素和维生素 D 类似物仍然是最常用、最广泛的银屑病外用疗法。总结虽然新型外用药物他匹那罗夫和罗氟司特已获得美国 FDA 批准用于治疗银屑病,但它们尚未在欧洲获得许可,而且它们是否会受到成本的限制还有待观察。
{"title":"An update on topical therapies for psoriasis.","authors":"Emily K Pender, Brian Kirby","doi":"10.1097/BOR.0000000000001018","DOIUrl":"https://doi.org/10.1097/BOR.0000000000001018","url":null,"abstract":"PURPOSE OF REVIEW\u0000Topical therapies are a mainstay of treatment for mild psoriasis and may be a useful adjunct in treatment of moderate-to-severe psoriasis. This review summarizes recent advances in topical therapies for psoriasis and currently available treatments.\u0000\u0000\u0000RECENT FINDINGS\u0000Topical aryl hydrocarbon receptor modulators (tapinarof) and topical phosphodiesterase-4 inhibitors (roflumilast) have been proven effective in randomized controlled trials for psoriasis. Although topical JAK inhibitors have also been studied, none are currently licensed for treatment of psoriasis. Topical corticosteroids and vitamin D analogues remain the most commonly used and widely available topical treatments for psoriasis. Cost may limit use of novel topical agents.\u0000\u0000\u0000SUMMARY\u0000Although the novel topical agents tapinarof and roflumilast are licensed for treatment of psoriasis by the FDA in the United States, they have not yet been licensed in Europe, and it remains to be seen whether they will be limited by cost.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140661784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug therapy in juvenile spondyloarthritis. 幼年脊柱关节炎的药物治疗。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-04-22 DOI: 10.1097/bor.0000000000001016
Hemalatha Srinivasalu, Jessica Simpson, Matthew L Stoll
This review summarizes latest developments in treatment of juvenile spondyloarthritis (JSpA), specifically enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).
本综述总结了幼年脊柱关节炎(JSpA)治疗的最新进展,特别是与关节炎相关的关节炎(ERA)和幼年银屑病关节炎(JPsA)。
{"title":"Drug therapy in juvenile spondyloarthritis.","authors":"Hemalatha Srinivasalu, Jessica Simpson, Matthew L Stoll","doi":"10.1097/bor.0000000000001016","DOIUrl":"https://doi.org/10.1097/bor.0000000000001016","url":null,"abstract":"This review summarizes latest developments in treatment of juvenile spondyloarthritis (JSpA), specifically enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140628472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of osteoarthritis: literature update 2022-2023. 骨关节炎的流行病学:2022-2023 年文献更新。
IF 5.2 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-03-01 Epub Date: 2023-10-19 DOI: 10.1097/BOR.0000000000000985
Mary Catherine C Minnig, Yvonne M Golightly, Amanda E Nelson

Purpose of review: This review highlights recently published studies on osteoarthritis (OA) epidemiology, including topics related to understudied populations and joints, imaging, and advancements in artificial intelligence (AI) methods.

Recent findings: Contemporary research has improved our understanding of the burden of OA in typically understudied regions, including ethnic and racial minorities in high-income countries, the Middle East and North Africa (MENA) and Latin America. Efforts have also been made to explore the burden and risk factors in OA in previously understudied joints, such as the hand, foot, and ankle. Advancements in OA imaging techniques have occurred alongside the developments of AI methods aiming to predict disease phenotypes, progression, and outcomes.

Summary: Continuing efforts to expand our knowledge around OA in understudied populations will allow for the creation of targeted and specific interventions and inform policy changes aimed at reducing disease burden in these groups. The burden and disability associated with OA is notable in understudied joints, warranting further research efforts that may lead to effective therapeutic options. AI methods show promising results of predicting OA phenotypes and progression, which also may encourage the creation of targeted disease modifying OA drugs (DMOADs).

综述目的:这篇综述重点介绍了最近发表的有关骨关节炎(OA)流行病学的研究,包括与研究不足的人群和关节、成像以及人工智能(AI)方法的进展有关的主题:当代研究提高了我们对通常研究不足地区的 OA 负担的认识,包括高收入国家、中东和北非(MENA)及拉丁美洲的少数族裔和种族。此外,研究人员还努力探索手部、足部和踝关节等以前未被充分研究的关节的 OA 负担和风险因素。OA 成像技术的进步与旨在预测疾病表型、进展和结果的人工智能方法的发展同步进行。总结:继续努力扩大我们对未充分研究人群 OA 的了解,将有助于制定有针对性的具体干预措施,并为旨在减少这些群体疾病负担的政策变化提供信息。在未充分研究的关节中,与 OA 相关的负担和残疾非常显著,因此需要进一步开展研究工作,从而找到有效的治疗方案。人工智能方法在预测 OA 表型和进展方面取得了可喜的成果,这也可能鼓励开发有针对性的改变 OA 疾病的药物(DMOADs)。
{"title":"Epidemiology of osteoarthritis: literature update 2022-2023.","authors":"Mary Catherine C Minnig, Yvonne M Golightly, Amanda E Nelson","doi":"10.1097/BOR.0000000000000985","DOIUrl":"10.1097/BOR.0000000000000985","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review highlights recently published studies on osteoarthritis (OA) epidemiology, including topics related to understudied populations and joints, imaging, and advancements in artificial intelligence (AI) methods.</p><p><strong>Recent findings: </strong>Contemporary research has improved our understanding of the burden of OA in typically understudied regions, including ethnic and racial minorities in high-income countries, the Middle East and North Africa (MENA) and Latin America. Efforts have also been made to explore the burden and risk factors in OA in previously understudied joints, such as the hand, foot, and ankle. Advancements in OA imaging techniques have occurred alongside the developments of AI methods aiming to predict disease phenotypes, progression, and outcomes.</p><p><strong>Summary: </strong>Continuing efforts to expand our knowledge around OA in understudied populations will allow for the creation of targeted and specific interventions and inform policy changes aimed at reducing disease burden in these groups. The burden and disability associated with OA is notable in understudied joints, warranting further research efforts that may lead to effective therapeutic options. AI methods show promising results of predicting OA phenotypes and progression, which also may encourage the creation of targeted disease modifying OA drugs (DMOADs).</p>","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139490048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases. 中性粒细胞失调在风湿性疾病发病机制中的研究进展。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-11-01 DOI: 10.1097/BOR.0000000000000986
Jianing Chen, Xinyu Wang, Yudong Liu, Xuan Zhang

Purpose of review: The exact pathogenic mechanisms of rheumatic diseases (RMD) remain largely unknown. Increasing evidence highlights a pathogenic role of neutrophil dysregulation in the development of RMD.

Recent findings: The purpose of this review is to present a current overview of recent advancements in understanding the role of neutrophil dysfunction in the development of RMD. Additionally, this review will discuss strategies for targeting pathways associated with neutrophil dysregulation as potential treatments for RMD. One specific aspect of neutrophil dysregulation, known as neutrophil extracellular traps (NETs), will be explored. NETs have been found to contribute to chronic pulmonary inflammation and fibrosis, as well as serve as DNA scaffolds for binding autoantigens, including both citrullinated and carbamylated autoantigens. Putative therapies, such as 6-gingerol or defibrotide, have demonstrated beneficial effects in the treatment of RMD by suppressing NETs formation.

Summary: Recent advances have significantly reinforced the crucial role of neutrophil dysregulation in the pathogenesis of RMD. A deeper understanding of the potential mechanisms underlying this pathogenic process would aid in the development of more precise and effective targeting strategies, thus ultimately improving the outcomes of RMD.

综述目的:风湿性疾病(RMD)的确切致病机制在很大程度上尚不清楚。越来越多的证据强调了中性粒细胞失调在RMD发展中的致病作用。最近的发现:本综述的目的是对理解中性粒细胞功能障碍在RMD发生中的作用的最新进展进行综述。此外,这篇综述将讨论靶向与中性粒细胞失调相关的通路的策略,作为RMD的潜在治疗方法。中性粒细胞失调的一个特定方面,即中性粒细胞外陷阱(NETs),将被探索。NETs被发现有助于慢性肺部炎症和纤维化,并作为结合自身抗原的DNA支架,包括瓜氨酸化和氨基甲酸化的自身抗原。推定疗法,如6-姜酚或降纤肽,已通过抑制NETs的形成,在治疗RMD方面显示出有益的效果。综述:最近的进展显著加强了中性粒细胞失调在RMD发病机制中的关键作用。更深入地了解这一致病过程的潜在机制将有助于制定更精确和有效的靶向策略,从而最终改善RMD的结果。
{"title":"Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases.","authors":"Jianing Chen, Xinyu Wang, Yudong Liu, Xuan Zhang","doi":"10.1097/BOR.0000000000000986","DOIUrl":"10.1097/BOR.0000000000000986","url":null,"abstract":"<p><strong>Purpose of review: </strong>The exact pathogenic mechanisms of rheumatic diseases (RMD) remain largely unknown. Increasing evidence highlights a pathogenic role of neutrophil dysregulation in the development of RMD.</p><p><strong>Recent findings: </strong>The purpose of this review is to present a current overview of recent advancements in understanding the role of neutrophil dysfunction in the development of RMD. Additionally, this review will discuss strategies for targeting pathways associated with neutrophil dysregulation as potential treatments for RMD. One specific aspect of neutrophil dysregulation, known as neutrophil extracellular traps (NETs), will be explored. NETs have been found to contribute to chronic pulmonary inflammation and fibrosis, as well as serve as DNA scaffolds for binding autoantigens, including both citrullinated and carbamylated autoantigens. Putative therapies, such as 6-gingerol or defibrotide, have demonstrated beneficial effects in the treatment of RMD by suppressing NETs formation.</p><p><strong>Summary: </strong>Recent advances have significantly reinforced the crucial role of neutrophil dysregulation in the pathogenesis of RMD. A deeper understanding of the potential mechanisms underlying this pathogenic process would aid in the development of more precise and effective targeting strategies, thus ultimately improving the outcomes of RMD.</p>","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71421648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health disparities in gout. 痛风的健康差异。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-12-22 DOI: 10.1097/BOR.0000000000000996
Lindsay N Helget, Ted R Mikuls

Purpose of review: Gout, the most common type of inflammatory arthritis in the world, is characterized by painful episodes of arthritis linked by asymptomatic intercritical periods of hyperuricemia. Once characterized as a disease of wealthy white men, contemporary evidence demonstrates gout disproportionately afflicts racial/ethnic minorities, Indigenous populations and other underrepresented groups leading to significant health disparities.

Recent findings: Herein, we review the current literature reporting a higher incidence and prevalence of gout in racial/ethnic minorities and Indigenous populations, in addition to a growing gout burden reported in females. We also examine how these population are more likely to receive suboptimal treatment for flares and chronic phases of gout. Additionally, we examine biologic and social health determinants that may be contributing to these findings.

Summary: Racial/ethnic minorities, Indigenous populations, and females have experienced a disproportionate rise in the prevalence and incidence of gout in recent years, are more likely to seek acute medical care and are less likely to receive optimal long-term care for gout with urate lowering therapy. Mechanisms underpinning these findings appear to be multifactorial and include differences in social determinants of care and in some cases may be due to population differences in select biologic factors such as differences in age, sex, genetics.

综述的目的:痛风是世界上最常见的炎症性关节炎,其特点是关节炎发作时疼痛难忍,并伴有无症状的高尿酸血症间歇期。痛风曾一度被认为是富裕白人男性的疾病,但当代证据表明,痛风对少数种族/民族、土著居民和其他代表性不足的群体的影响格外严重,导致了严重的健康差异:在此,我们回顾了当前的文献报道,痛风在少数种族/民族和原住民中的发病率和流行率较高,此外,女性痛风患者的负担也在不断加重。我们还研究了这些人群如何更有可能在痛风发作期和慢性期接受次优治疗。此外,我们还研究了可能导致这些发现的生物和社会健康决定因素:近年来,少数种族、原住民和女性痛风的患病率和发病率出现了不成比例的上升,他们更有可能寻求急性医疗护理,但却不太可能通过降低尿酸盐治疗获得最佳的痛风长期护理。导致这些发现的机制似乎是多因素的,其中包括医疗保健的社会决定因素的差异,在某些情况下,可能是由于选定的生物因素(如年龄、性别和遗传学差异)的人群差异造成的。
{"title":"Health disparities in gout.","authors":"Lindsay N Helget, Ted R Mikuls","doi":"10.1097/BOR.0000000000000996","DOIUrl":"10.1097/BOR.0000000000000996","url":null,"abstract":"<p><strong>Purpose of review: </strong>Gout, the most common type of inflammatory arthritis in the world, is characterized by painful episodes of arthritis linked by asymptomatic intercritical periods of hyperuricemia. Once characterized as a disease of wealthy white men, contemporary evidence demonstrates gout disproportionately afflicts racial/ethnic minorities, Indigenous populations and other underrepresented groups leading to significant health disparities.</p><p><strong>Recent findings: </strong>Herein, we review the current literature reporting a higher incidence and prevalence of gout in racial/ethnic minorities and Indigenous populations, in addition to a growing gout burden reported in females. We also examine how these population are more likely to receive suboptimal treatment for flares and chronic phases of gout. Additionally, we examine biologic and social health determinants that may be contributing to these findings.</p><p><strong>Summary: </strong>Racial/ethnic minorities, Indigenous populations, and females have experienced a disproportionate rise in the prevalence and incidence of gout in recent years, are more likely to seek acute medical care and are less likely to receive optimal long-term care for gout with urate lowering therapy. Mechanisms underpinning these findings appear to be multifactorial and include differences in social determinants of care and in some cases may be due to population differences in select biologic factors such as differences in age, sex, genetics.</p>","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccination updates and special considerations for systemic lupus erythematosus patients. 系统性红斑狼疮患者的疫苗接种更新和特殊考虑。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-11-16 DOI: 10.1097/BOR.0000000000000992
Jammie Law, Cristina Sorrento, Amit Saxena

Purpose of review: We review the latest guidelines and note special considerations for systemic lupus erythematosus (SLE) patients when approaching vaccination against SARS-CoV-2, influenza, pneumococcus, herpes zoster, and potentially respiratory syncytial virus (RSV) vaccine in the future.

Recent findings: SLE patients have unique infectious risks due to newer treatments and the nature of the disease itself. It is important to balance the benefit of additional protective immunity from updated vaccines against the possible risk of disease activity exacerbations.

Summary: It is important to continuously evaluate the safety and immunogenicity of updated vaccines specifically for SLE patients. Additionally, the newly approved RSV vaccine should be considered for this population to reduce severe respiratory illness.

回顾的目的:我们回顾了最新的指南,并注意到系统性红斑狼疮(SLE)患者在将来接种SARS-CoV-2、流感、肺炎球菌、带状疱疹和潜在的呼吸道合胞病毒(RSV)疫苗时的特殊注意事项。最新发现:由于较新的治疗方法和疾病本身的性质,SLE患者具有独特的感染风险。重要的是要平衡更新疫苗带来的额外保护性免疫的益处与疾病活动加剧的可能风险。总结:持续评估针对SLE患者的新疫苗的安全性和免疫原性是非常重要的。此外,新批准的RSV疫苗应考虑用于这一人群,以减少严重的呼吸道疾病。
{"title":"Vaccination updates and special considerations for systemic lupus erythematosus patients.","authors":"Jammie Law, Cristina Sorrento, Amit Saxena","doi":"10.1097/BOR.0000000000000992","DOIUrl":"10.1097/BOR.0000000000000992","url":null,"abstract":"<p><strong>Purpose of review: </strong>We review the latest guidelines and note special considerations for systemic lupus erythematosus (SLE) patients when approaching vaccination against SARS-CoV-2, influenza, pneumococcus, herpes zoster, and potentially respiratory syncytial virus (RSV) vaccine in the future.</p><p><strong>Recent findings: </strong>SLE patients have unique infectious risks due to newer treatments and the nature of the disease itself. It is important to balance the benefit of additional protective immunity from updated vaccines against the possible risk of disease activity exacerbations.</p><p><strong>Summary: </strong>It is important to continuously evaluate the safety and immunogenicity of updated vaccines specifically for SLE patients. Additionally, the newly approved RSV vaccine should be considered for this population to reduce severe respiratory illness.</p>","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microbiome dynamics in rheumatic diseases. 风湿病的微生物动力学。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-03-01 Epub Date: 2023-11-16 DOI: 10.1097/BOR.0000000000000993
Yiqing Wang, Zijun Wang, Qianjin Lu

Purpose of review: Rheumatic disease are characterized by their autoimmune nature, frequently affecting joints, bones, muscles, blood vessels, and connective tissues. The onset of these conditions typically unfolds gradually and subtly. It is noteworthy that individuals with rheumatic diseases often experience shifts in their microbiome, specifically on mucosal surfaces. The purpose of this review is to delve into the intricate interplay between the microbiome, encompassing bacteria, viruses and fungi, and its role in the development and aggravation of various rheumatic diseases. Additionally, it aims to offer insights into microbiome-centered therapeutic approaches for patients in the field of rheumatology.

Recent findings: The advent of next-generation sequencing has significantly improved our understanding of microbiome changes. Numerous studies have consistently revealed a strong link between rheumatism and the microbiome, especially in the oral and gut microbiota.

Summary: A deeper comprehension of the microbiome's connection to rheumatism holds potential for enhancing disease diagnosis and treatment. Targeted therapeutic approaches, including probiotics, fecal microbiota transplantation, and combination therapies with medications, offer promising avenues for disease management.

综述目的:风湿性疾病的特点是其自身免疫性,经常影响关节、骨骼、肌肉、血管和结缔组织。这些症状的发作通常是缓慢而微妙的。值得注意的是,患有风湿性疾病的个体经常经历微生物组的变化,特别是在粘膜表面。本综述的目的是深入研究微生物群(包括细菌、病毒和真菌)之间复杂的相互作用,及其在各种风湿性疾病的发展和加重中的作用。此外,它旨在为风湿病领域的患者提供以微生物组为中心的治疗方法。最新发现:下一代测序的出现大大提高了我们对微生物组变化的理解。大量研究一致表明,风湿病与微生物群,特别是口腔和肠道微生物群之间存在密切联系。总结:对微生物组与风湿病的联系的更深入的理解有可能提高疾病的诊断和治疗。有针对性的治疗方法,包括益生菌、粪便微生物群移植和药物联合治疗,为疾病管理提供了有希望的途径。
{"title":"Microbiome dynamics in rheumatic diseases.","authors":"Yiqing Wang, Zijun Wang, Qianjin Lu","doi":"10.1097/BOR.0000000000000993","DOIUrl":"10.1097/BOR.0000000000000993","url":null,"abstract":"<p><strong>Purpose of review: </strong>Rheumatic disease are characterized by their autoimmune nature, frequently affecting joints, bones, muscles, blood vessels, and connective tissues. The onset of these conditions typically unfolds gradually and subtly. It is noteworthy that individuals with rheumatic diseases often experience shifts in their microbiome, specifically on mucosal surfaces. The purpose of this review is to delve into the intricate interplay between the microbiome, encompassing bacteria, viruses and fungi, and its role in the development and aggravation of various rheumatic diseases. Additionally, it aims to offer insights into microbiome-centered therapeutic approaches for patients in the field of rheumatology.</p><p><strong>Recent findings: </strong>The advent of next-generation sequencing has significantly improved our understanding of microbiome changes. Numerous studies have consistently revealed a strong link between rheumatism and the microbiome, especially in the oral and gut microbiota.</p><p><strong>Summary: </strong>A deeper comprehension of the microbiome's connection to rheumatism holds potential for enhancing disease diagnosis and treatment. Targeted therapeutic approaches, including probiotics, fecal microbiota transplantation, and combination therapies with medications, offer promising avenues for disease management.</p>","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vasculitis and the NLRP3 inflammasome. 血管炎和NLRP3炎性体。
IF 5.1 2区 医学 Q1 Medicine Pub Date : 2024-01-01 Epub Date: 2023-08-13 DOI: 10.1097/BOR.0000000000000962
Kamel Hamzaoui, Agnès Hamzaoui

Purpose of review: Vasculitis are a group of heterogeneous conditions characterized by chronic inflammation of blood vessels, leading to tissue destruction and organ failure. Vasculitis is an inflammatory process in which immune effector cells infiltrate blood vessels and surrounding tissues. The involvement of inflammasomes seems to occur during inflammatory processes.

Recent findings: Studies have emphasized that genetic susceptibility is an important aspect of the pathogenesis of vasculitis. The innate immune system is a major contributor to these inflammatory diseases, suggesting that the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome plays a key role. NLRP3 activation causes the assembly of a large multiprotein and leads to the secretion of bioactive interleukin (IL)-1β and IL-18 as well as the induction of inflammatory cell death, termed pyroptosis. Accumulating evidence confirms the involvement of this cascade in sterile inflammatory diseases and other vascular diseases.

Summary: In this review, we will summarize the current state of knowledge regarding the role of NLRP3 inflammasome in vascular diseases, and discuss the potential of the NLRP3 inflammasome as a therapeutic target.

综述目的:血管炎是一组以血管慢性炎症为特征的异质性疾病,可导致组织破坏和器官衰竭。血管炎是免疫效应细胞浸润血管和周围组织的炎症过程。炎性小体的参与似乎发生在炎症过程中。最新发现:研究强调遗传易感性是血管炎发病机制的一个重要方面。先天免疫系统是这些炎症性疾病的主要诱因,这表明含有3 (NLRP3)炎症小体的nod样受体家族pyrin结构域起关键作用。NLRP3的激活导致大量多蛋白的聚集,导致生物活性白介素(IL)-1β和IL-18的分泌,并诱导炎症细胞死亡,称为焦亡。越来越多的证据证实这种级联反应参与无菌性炎症性疾病和其他血管疾病。摘要:在这篇综述中,我们将总结NLRP3炎性小体在血管疾病中的作用,并讨论NLRP3炎性小体作为治疗靶点的潜力。
{"title":"Vasculitis and the NLRP3 inflammasome.","authors":"Kamel Hamzaoui, Agnès Hamzaoui","doi":"10.1097/BOR.0000000000000962","DOIUrl":"10.1097/BOR.0000000000000962","url":null,"abstract":"<p><strong>Purpose of review: </strong>Vasculitis are a group of heterogeneous conditions characterized by chronic inflammation of blood vessels, leading to tissue destruction and organ failure. Vasculitis is an inflammatory process in which immune effector cells infiltrate blood vessels and surrounding tissues. The involvement of inflammasomes seems to occur during inflammatory processes.</p><p><strong>Recent findings: </strong>Studies have emphasized that genetic susceptibility is an important aspect of the pathogenesis of vasculitis. The innate immune system is a major contributor to these inflammatory diseases, suggesting that the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome plays a key role. NLRP3 activation causes the assembly of a large multiprotein and leads to the secretion of bioactive interleukin (IL)-1β and IL-18 as well as the induction of inflammatory cell death, termed pyroptosis. Accumulating evidence confirms the involvement of this cascade in sterile inflammatory diseases and other vascular diseases.</p><p><strong>Summary: </strong>In this review, we will summarize the current state of knowledge regarding the role of NLRP3 inflammasome in vascular diseases, and discuss the potential of the NLRP3 inflammasome as a therapeutic target.</p>","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10006782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current opinion in rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1